Sphingomyelin in Lewy Inclusion Bodies in Parkinson's Disease

1969/12/01 by W. A. den Hartog Jager, Wander Jager, Gemma Fajardo García · 26 citations
Business, Management and Accounting · Environmental Science · Medicine · Neuroscience · Psychology · Social Sciences · #Biology #Cooperative Studies and Economics #Disease #Finance, Taxation, and Governance #Inclusion bodies #Lewy body #Locus Ceruleus #Medicine #Neurological diseases and metabolism #Neurological disorders and treatments #Neuroscience #Parkinson's Disease Mechanisms and Treatments #Parkinson's disease #Parkinsonism #Pathology #Psychology #Social Sciences and Policies #Substantia nigra

paper · doi:10.1001/archneur.1969.00480180071006

openalex publication_date 1969/12/01 · openalex created_date 2016/06/24 · openalex updated_date 2026/07/15

Abstract

THE INCLUSION bodies, which were later to receive his name, were first described by Lewy 1 in the substantia innominata and the dorsal vagal nucleus in paralysis agitans. Tretiakoff 2 described these bodies in the substantia nigra. Greenfield and Bosanquet 3 found Lewy bodies in the substantia nigra in 18 of 19 cases of idiopathic paralysis agitans and in the locus ceruleus in the 19th case (substantia nigra not present). In none of the ten cases of postencephalitic parkinsonism and none of the 22 control subjects of the same age but without parkinsonism were Lewy bodies found. Lipkin 4 studied 53 patients with Parkinson's disease and found Lewy bodies in 44% of the postencephalitic cases and 86% of the idiopathic cases. Bethlem and den Hartog Jager 5 corroborated the findings of Greenfield and Bosanquet 3 in an investigation of the substantia nigra and locus ceruleus in 15 patients with

Cited by

• The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α‐synuclein aggregates
• Immunoreactivity of myelin‐associated oligodendrocytic basic protein in Lewy bodies
• Membrane remodeling and mechanics: Experiments and simulations of α-Synuclein. [europepmc]
• Interplay between α-synuclein amyloid formation and membrane structure. [europepmc]
• The Role of Lipids in Parkinson's Disease. [europepmc]
• Inhibition of nSMase2 Reduces the Transfer of Oligomeric α-Synuclein Irrespective of Hypoxia. [europepmc]
• Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let's talk about the lipids in the room. [europepmc]
• The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. [europepmc]
• A Stearoyl-Coenzyme A Desaturase Inhibitor Prevents Multiple Parkinson Disease Phenotypes in α-Synuclein Mice. [europepmc]
• The Role of Lipids in the Initiation of α-Synuclein Misfolding. [europepmc]
• Alteration in the Cerebrospinal Fluid Lipidome in Parkinson's Disease: A Post-Mortem Pilot Study. [europepmc]
• The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy. [europepmc]
• Alpha-Synuclein and the Endolysosomal System in Parkinson's Disease: Guilty by Association. [europepmc]
• The Sphingolipid Asset Is Altered in the Nigrostriatal System of Mice Models of Parkinson's Disease. [europepmc]
• Human Brain Lipidomics: Pilot Analysis of the Basal Ganglia Sphingolipidome in Parkinson's Disease and Lewy Body Disease. [europepmc]
• A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity. [europepmc]
• Altered expression of glycobiology-related genes in Parkinson's disease brain. [europepmc]
• Taking Charge: Metal Ions Accelerate Amyloid Aggregation in Sequence Variants of α-Synuclein. [europepmc]
• Distribution of phosphorylated alpha-synuclein in non-diseased brain implicates olfactory bulb mitral cells in synucleinopathy pathogenesis. [europepmc]
• α-Synuclein fibril and synaptic vesicle interactions lead to vesicle destruction and increased lipid-associated fibril uptake into iPSC-derived neurons. [europepmc]
• Role of Lipids in the Pathogenesis of Parkinson's Disease. [europepmc]
• Double-Negative CD4 CD8 Absolute Count Plays a Mediating Role in the Causal Relationship Between Plasma Lipids and Parkinson's Disease: A Mendel Randomized Study. [europepmc]
• Stearoyl-CoA desaturase inhibition normalizes brain lipid saturation, α-synuclein homeostasis, and motor function in mutant Gba1-Parkinson mice. [europepmc]
• Mapping the Role of Monomer Conformation in the Amyloid Formation of α-Synuclein Splice Variants. [europepmc]
• Multiomic Analysis Reveals Molecular Pathways Associated with Intestinal Aggregation of α-Synuclein. [europepmc]
• α-Synuclein in Lewy Body Diseases: Progress, Remaining Challenges and Future Perspectives. [europepmc]

Related

• Lafora and Trétiakoff: the naming of the inclusion bodies discovered by Lewy
• Lewy and his inclusion bodies: Discovery and rejection
• Lewy body disease and dementia with Lewy bodies
• PHASE AND ELECTRON MICROSCOPIC OBSERVATIONS OF LEWY BODIES AND MELANIN GRANULES IN THE SUBSTANTIA NIGRA AND LOCUS CAERULEUS IN PARKINSONʼS DISEASE
• Lewy body disease or diseases with Lewy bodies?